Searched for
KREMERS URBAN
Economy in tailspin…doing very badly, says Nobel laureate Abhijit BanerjeeAbhijit Banerjee has repeatedly expressed concern over the slowing growth of the Indian economy, saying it was time India stopped worrying ...- InvaGen, Exelan acquisition will give Cipla manufacturing plant, R&D base in USCipla on Friday fulfilled a longstanding desire to expand its beachhead in the US by buying Hetero Pharma’s US business for about $550 mill...
- Cipla set to buy American business of Hetero Drugs for $550 millionPeople close to the transaction said Cipla will buy Invagen and Camber, Hetero’s wholly owned subsidiary, for about $550 million.
- Cipla not keen on major M&As to expand footprint: CEO Subhanu SaxenaCipla has said it is not "compelled" to go in for major M&As, preferring instead a semi-inorganic route to expand its global footprint.
- Cipla ends 3% down even as company only Indian firm in race for Kremers UrbanIndia's third largest drug maker posted a net profit of Rs 294.58 crore for the corresponding period of the previous fiscal year.
- Cipla only Indian firm in race for Kremers UrbanIf Cipla is able to close it, the deal, pegged at around $1.3 billion, will eclipse Lupin’s recent $880 million buyout of Gavis Pharma.
- Sensex up over 150 points; Nifty reclaims 8,500; Sun TV cracks 3%, Tata Coffee up 9%The 50-share Nifty index surged past its crucial psychological level of 8500, supported by gains in IT, auto, capital goods, metal and real...
- Twelve stocks in focus in Tuesday's tradeIndian markets are expected to trade in a range. Here is a list of twelve stocks which are likely to remain in focus today.
- Indian companies in FDA's first list for generic Aciphex tabletsIndian firms including Dr Reddy's, Lupin and Torrent Pharma have received nod from the US health regulator to market the first generic vers...
- Panacea Biotech enters into pact with Kremers Urban; stock upShares of Panacea Biotech gained momentum after the company entered into strategic alliance with Kremers Urban for 11 high barrier to entry...
Load More
